Table 3.

Metabolic Parameters at Baseline and After 8 Weeks of Intervention

Parameter	Group	Baseline	Wk 8	Δ (Wk 8 − Baseline)	P Value
					Baseline	Δ Between Group
Weight, kg	Placebo	102 ± 29	101 ± 29	−0.4 ± 2.4	.59	.79
	Sitagliptin	97 ± 21	97 ± 20	−0.6 ± 2.3
BMI, kg/m2	Placebo	33.1 ± 8.2	32.7 ± 8.1	−0.3 ± 1.2	.91	.57
	Sitagliptin	32.7 ± 8.2	32.6 ± 8.4	−0.1 ± 1.1
Fasting glucose, mg/dL	Placebo	97.7 ± 7.9	94.4 ± 7.9	−3.3 ± 5.6	.72	.47
	Sitagliptin	96.8 ± 7.5	92.2 ± 6.9	−4.6 ± 5.3
Fasting insulin, μU/mL	Placebo	17.9 ± 10.7	15.5 ± 13.8	−2.4 ± 8.0	.03	.24
	Sitagliptin	11.4 ± 6.0	11.6 ± 6.4	0.2 ± 3.9
HOMA-IR	Placebo	4.3 ± 2.8	3.8 ± 3.8	−0.5 ± 2.0	.04	.39
	Sitagliptin	2.7 ± 1.5	2.6 ± 1.5	−0.1 ± 1.0
HOMA-%β	Placebo	185 ± 111	171 ± 115	−13 ± 152	.04	.36
	Sitagliptin	120 ± 66	149 ± 93	29 ± 118
OGIS120, mL/min/m2 BSA	Placebo	362 ± 60	340 ± 64	−22 ± 68	.46	.04
	Sitagliptin	347 ± 62	366 ± 60	19 ± 40
IGI	Placebo	190 ± 89	178 ± 73	−12 ± 58	.88	.15
	Sitagliptin	195 ± 122	225 ± 142	30 ± 106
oGTT glucose AUC	Placebo	17 697 ± 1823	16 369 ± 2605	−1327 ± 2158	.52	.002
	Sitagliptin	18 092 ± 1852	14 720 ± 2291	−3372 ± 1396
oGTT insulin AUC	Placebo	12 454 ± 6783	11 974 ± 8110	−480 ± 6450	.97	.78
	Sitagliptin	12 368 ± 7973	11 307 ± 8228	−1061 ± 6106
oGTT C-peptide AUC	Placebo	1191 ± 321	1200 ± 468	9 ± 291	.88	.56
	Sitagliptin	1140 ± 355	1099 ± 329	−45 ± 250
oGTT glucagon AUC	Placebo	8016 ± 1629	7902 ± 1400	−114 ± 769	.25	.42
	Sitagliptin	8792 ± 2300	8405 ± 2788	−387 ± 1197
Fasting serum triglycerides, mg/dL	Placebo	155 ± 106	140 ± 68	−14 ± 78	.03	.21
	Sitagliptin	94 ± 44	107 ± 61	13 ± 45
Total cholesterol, mg/dL	Placebo	178 ± 26	171 ± 25	−7 ± 21	.15
	Sitagliptin	163 ± 34	165 ± 40	2 ± 21
LDL cholesterol, mg/dL	Placebo	101 ± 33	97 ± 27	−4 ± 18	.48	.32
	Sitagliptin	94 ± 28	96 ± 30	2 ± 18
HDL cholesterol, mg/dL	Placebo	48 ± 17	46 ± 16	−2 ± 6	.67	.92
	Sitagliptin	51 ± 18	48 ± 18	−3 ± 7

Data are expressed as mean ± SD.